Fusion Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Fusion Pharmaceuticals generated cash of -$81,802,000, which is less than the previous year. Cash used in financing activities reached the amount of $142,006,000 last year. Net change in cash is therefore $17,610,000.
Cash Flow
| 2017 | -6.12M | -96K | 27.17M |
|---|---|---|---|
| 2018 | -9.86M | -1.12M | 18.36M |
| 2019 | -13.69M | -456K | 52.18M |
| 2020 | -29.76M | -210.45M | 265.50M |
| 2021 | -75.74M | 37.77M | 347K |
| 2022 | -73.27M | 23.08M | 40.73M |
| 2023 | -81.80M | -42.76M | 142.00M |
FUSN Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 44.31M | 54.78M | 92.40M | 67.12M | 29.08M | 21.7M | 750K |
Operating activities | |||||||
Net income | -94.89M | -87.61M | -81.04M | -78.33M | -16.18M | -11.65M | -6.26M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.34M | 909K | 634K | 482K | 290K | 114K | 23K |
Stock-based compensation expense | 12.44M | 10.84M | 8.60M | 3.36M | 618K | 0 | 112K |
| Deferred income tax benefit | 12.44M | 10.84M | 8.60M | 3.36M | 618K | 0 | 112K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 54K | 296K | -357K | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | -12.09M | 0 | 0 | 0 | 0 |
Accounts payable | -721K | 400K | -1.18M | 2.55M | 479K | -381K | 589K |
Cash generated by operating activities | -81.80M | -73.27M | -75.74M | -29.76M | -13.69M | -9.86M | -6.12M |
Investing activities | |||||||
Purchases Of Investments | -230.57M | -165.15M | -172.46M | -219.03M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.89M | -2.14M | -1.49M | -1.12M | -456K | -1.12M | -96K |
Acquisitions Net | 38.87M | -25.22M | -39.26M | -9.7M | 0 | 0 | 0 |
Cash generated by investing activities | -42.76M | 23.08M | 37.77M | -210.45M | -456K | -1.12M | -96K |
Financing activities | |||||||
Common Stock Issued | 142.00M | 5.81M | 347K | 197.62M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 1.28M | 0 | -72.39M | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -72.39M | 0 | 0 | 0 |
Cash used in financing activities | 142.00M | 40.73M | 347K | 265.50M | 52.18M | 18.36M | 27.17M |
Net Change In Cash | 17.61M | -9.45M | -37.61M | 25.28M | 38.04M | 7.38M | 20.95M |
Cash at end of period | 61.92M | 45.33M | 54.78M | 92.40M | 67.12M | 29.08M | 21.7M |
| Data source | Data source | Data source | Data source |